Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. (Pacira) on October 11, 2021. The filing primarily announces the entry into a definitive merger agreement to acquire Flexion Therapeutics, Inc. (Flexion). Additionally, the report references preliminary unaudited revenue figures for Pacira for the month and quarter ended September 30, 2021, though specific numerical values for these figures are not provided within the text of this filing.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed acquisition of Flexion rather than Pacira's standalone financial performance metrics (such as profit, cash flow, or debt) for the period.
- Offer Price: $8.50 per share in cash, net of applicable withholding taxes.
- Contingent Value Rights (CVRs): One CVR per share, representing the right to receive up to $8.00 in aggregate milestone payments.
- Termination Fee: $18.0 million payable by Flexion to Pacira if Flexion terminates the agreement to accept a superior offer.
- Supporting Stockholders: Flexion directors and executive officers beneficially own approximately 4.4% of outstanding shares and have agreed to tender their shares.
Material Changes and Milestone Payments
The primary material change is the execution of the Merger Agreement. The transaction includes specific contingent payments tied to future performance milestones, which must be achieved on or before December 31, 2030:
- ZILRETTA Sales Milestones:
- $1.00 per CVR upon net sales reaching $250.0 million in a calendar year.
- $2.00 per CVR upon net sales reaching $375.0 million in a calendar year.
- $3.00 per CVR upon net sales reaching $500.0 million in a calendar year.
- Regulatory Approval Milestones:
- $1.00 per CVR upon FDA approval of a Biologics License Application (BLA) for FX-201 (gene therapy).
- $1.00 per CVR upon FDA approval of a New Drug Application (NDA) for FX-301.
Flexion options and restricted stock units (RSUs) will accelerate and vest immediately prior to the effective time of the merger, with specific conversion rules based on exercise prices relative to the cash offer price.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated benefits of the acquisition, integration plans, and future financial results. Management has disclaimed any obligation to update these statements. Key risks and contingencies identified include:
- Transaction Completion: Risks related to the ability to complete the transaction, including the satisfaction of tender offer conditions (e.g., receiving more than 50% of shares) and regulatory approvals.
- Milestone Achievement: No assurance that the sales or regulatory milestones for the CVRs will be achieved.
- Integration and Operations: Risks associated with integrating Flexion, potential disruption to business operations, and the impact of the COVID-19 pandemic.
- Competing Offers: The possibility of competing offers or the failure to receive required regulatory approvals.
Investor Verification Checklist
- Verify the specific preliminary revenue numbers for the month and quarter ended September 30, 2021, in the attached Press Release (Exhibit 99.1) as they are not detailed in the main text.
- Review the full Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and conditions precedent to the closing.
- Examine the CVR Agreement (Exhibit C to the Merger Agreement) for the precise definitions of "net sales" and the specific terms governing the milestone payments.
- Monitor the filing of the Tender Offer Statement (Schedule TO) and Solicitation/Recommendation Statement (Schedule 14D-9) for the official commencement of the offer.
- Assess the financial impact of the $18.0 million termination fee and the potential liability of the CVRs on Pacira's future balance sheet.